Phd in HUMAN BIOLOGY AND MEDICAL GENETICS

email: laura.stronati@uniroma1.it
phone:
building: V Clinica Medica (PL028)
room: 304

GENERAL INFORMATION
Full Name: LAURA STRONATI
Citizenship: ITALIAN
Spoken Languages: Italian, English

EDUCATION
University graduation: 1986, Sapienza University of Rome, Biological Sciences, full marks and honors;
Post-graduate studies: 1986-89, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), Post-graduate guest;
National qualification: 2012, Italian Ministry of Education, Qualification University and Research (MIUR) - ANVUR, Abilitazione Scientifica Nazionale professore di II FASCIA 05/F1;
2012, Italian Ministry of Education, Qualification University and Research (MIUR) - ANVUR, Abilitazione Scientifica Nazionale professore di II FASCIA 05/E2;
2013, Italian Ministry of Education, Qualification University and Research (MIUR) - ANVUR, Abilitazione Scientifica Nazionale professore di II FASCIA 06/N1;
2016, Italian Ministry of Education, Qualification University and Research (MIUR) - ANVUR, Abilitazione Scientifica Nazionale professore di I FASCIA 05/F1.

ACADEMIC APPOINTMENTS
01/11/2023 - today, Sapienza University of Rome, Department of Molecular Medicine, Full Professor (BIO/13);
30/10/2015 -Today, Sapienza University of Rome, Department of Cellular Biotechnology and Haematology, Associate Professor (BIO/13);
01/11/2019- Today, Sapienza University of Rome, Department of Molecular Medicine, Coordinator of PhD in Human Biology and Medical Genetics;
09/03/2023- Today, Sapienza University of Rome, Department of Molecular Medicine, Member of the Departmental Commission “Terza Missione”.

OTHER APPOINTMENTS
2011-2015, ENEA, Senior Researcher
1990-2011, ENEA, Researcher
1989-1990, ENEA, Consultant

TEACHING EXPERIENCE
2020-today, Sapienza University of Rome, Genetics in the graduate program of Medicine High Technology
2020-today, Sapienza University of Rome, Applied Biology in the graduate program of Dietetics (Sapienza University of Rome)
2021-today, Sapienza University of Rome, Molecular Biology at Master of II level in Gastrointestinal imaging
2016-today, Sapienza University of Rome, Cell biology in the graduate program of Biotechnology (Coordinator 1 semester)
2016-today, Sapienza University of Rome, Applied biology in the graduate program of Biomedical Laboratory Techniques
2020-2022, Sapienza University of Rome, Biology and Genetics in the graduate program of Medicine, course B (Coordinator of the integrated course)
2016-2020, Sapienza University of Rome, Cell biology in the graduate program of Biomedical Biotechnology at Sapienza
2017-2020, Sapienza University of Rome, Applied biology in the graduate program of Occupational Therapy
2011-2015, Sapienza University of Rome, Biochemistry in the graduate program of Pediatric Nursing
2012-2015, Sapienza University of Rome, Genetics in the graduate program of Technical Neurophysiopathology
2005-2015, Sapienza University of Rome, Molecular Biology at Master of II level in Pediatric Gastroenterology, Hepatology and Digestive Endoscopy
2006-2008, University of Rome Tor Vergata, Genetics in the graduate program of Techniques for the Prevention of Accidents in the Workplace
2003-2005, University of Rome Tor Vergata, Medical Genetics in the graduate program of Physiotherapy

MENTORING EXPERIENCE
-Supervisor of Bachelor and Master’s degree students in Biology and Biotechnology.
-Supervisor of PhD students.
-Supervisor of Master II Level students.

EDITORIAL ACTIVITY
2022-to present, Associate Editor of Frontiers in Immunology
2018-to present, Associate Editor of Digestive and Liver Disease (Elsevier)

FUNDING (last 5 years)
2022-24,“Creazione di un’infrastruttura di innovazione, servizio, formazione, terza missione e ricerca aperta e distribuita sul territorio, finalizzata a supportare la creazione e sviluppo di dispositivi medici”, (Role: I), Rome Technopole - Progetto Flagship 4 (Prot. RT422184581348BF), (1.416.250,00 euro);
2023-25, "Integrated phenotyping of the Gut-platelet-Liver AXIS in the progression of chronic liver disease. (iGAL-AXIS), (Role: I), PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE – Bando 2022 Prot. 2022C7ZR3W (258,041 euro);
2020-22, ”Immunosensori modificati con materiale nanostrutturato per la rilevazione di biomarcatori fecali di infiammazione e permeabilità intestinale: un importante progresso nella gestione di malattie ad alta prevalenza” PaGIMeter, (Role: I) Progetto Strategico della Regione Lazio prot. n. A320-2019-28176 del 29/07/2019 (252,172,69 euro);
2022, “Multiomics and machine learning to predict response to drug therapies in pediatric Eosinophilic Esophagitis”, (Role: PI), Progetto Ateneo Grande Prot. RG1221816730E1E0 (73.890,08 euro);
2021, "Examining intestinal fibrosis in patients with Crohn's disease using organoid models", (Role: PI), Progetto Ateneo medio Prot. RM12117A757B9F08 (10.000,00 euro);
2021, “Studio in vitro degli effetti di Scutellaria Baicalensis Georgi e Boswellia serrata sulla fibrosi intestinale”, (Role: PI), Progetto finanziato da Cadigroup Farmaceutici Srl (15.000,00 euro);
2020, “Characterization of the esophageal tissue by single cell RNA sequencing in pediatric patients with oesinophilic esophagitis and identification of novel biomarkers to predict the early-relapse to the disease”, (Role: PI), Progetto Ateneo medio Prot. RM120172B43331E2 (10.000,00 euro);
2019, "Role of gut-liver axis in Non-Alcoholic Steatohepatitis (NASH)”, (Role: PI), Progetto Ateneo medio Prot. RM11916B8881A306 (10.000,00 euro);


RESEARCH ACTIVITIES
Keywords: Immunopathogenesis, chronic inflammatory disorders,inflammation,fibrosis, GI tract.
-Immunopathonesis of inflammatpry diseases of the GI tract: I’ve been studying for many years the pathogenetic mechanisms underlying the onset and progression of intestinal inflammation in several pathologies of the gastrointestinal tract (GI), including Inflammatory Bowel Disease (IBD), eosinophilic esophagitis (EoE), celiac disease (CD). Particular attention has been given to proteins of innate immunity, such as NOD2, RIP2, HMGB1, with a primary role in the inflammatory response. More recently, my studies have focused on the role of the transcription factor ZNF281 and its interactors in promoting intestinal inflammation and fibrosis.
-Biomarkers: I’ve been identifying novel fecal biomarkers of inflammation as reliable and non-invasive tools for the diagnosis and disease course assessment of several GI disorders, principally IBD. Up to now, four new markers have been identified: HMGB1, Rho GDI2, Chymotrypsin C, Gelsolin; the first two are the subject of a patent application and release.
-Gut microbiota metagenomics:I’ve been analyzing the composition of gut-microbiota in patients with chronic disorders (IBD, metabolic syndrome, autism spectrum disorders (ASD)) by next-generation sequencing (shotgun metagenomics).
-Gut-liver axis: I have been investigating the molecular mechanisms underlying the onset of Non-Alcoholic Fatty Liver Disease (NAFLD) and its progression to steatohepatitis (NASH) in pediatric patients and the relationship between intestinal and hepatic diseases realizing the gut-liver axis.
-Nonpharmacological molecules therapy: I have been studying the anti-inflammatory and anti-fibrotic properties of molecules of a non-pharmacological nature (glycyrrhetic acid, omega three, Boswellia serrata extract, Scutellaria baicalensis Georgi extract) to be used for the therapeutic management of chronic inflammatory disorders.

SCIENTIFIC ACHIEVEMENTS
Papers [international]: 92 (https://pubmed.ncbi.nlm.nih.gov/)
Books [scientific]:1, Springer (ISBN: 8847014719)
Hirsch (H) index (https://www.scopus.com/): 37

PATENT
2014, Titolo: “Uso di HMGB1 come marcatore biologico di infiammazione”, Numero di pubblicazione: WO 2014/017466 A1, N. rilascio:1406051, Data di rilascio: 06.02.2014.
2019, Titolo: “Uso della proteina inibitore 2 della dissociazione di RHO GDP come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” Numero di pubblicazione: WO 2019/016719 A, N. rilascio: 102017000083055, Data di rilascio: 08.10.2019